Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study
Indu S Voruganti Maddali,Cicely Cunningham,Lorraine McLeod,Houda Bahig,Nazia Chaudhuri,Kevin L M Chua,Matthew Evison,Corinne Faivre-Finn,Kevin Franks,Susan Harden,Gregory Videtic,Percy Lee,Suresh Senan,Shankar Siva,David A Palma,Iain Phillips,Jacqueline Kruser,Timothy Kruser,Clive Peedell,X Melody Qu,Clifford Robinson,Angela Wright,Stephen Harrow,Alexander V Louie
DOI: https://doi.org/10.1016/j.lungcan.2024.107822
IF: 6.081
Lung Cancer
Abstract:Purpose: Radiation pneumonitis (RP) is a dose-limiting toxicity for patients undergoing radiotherapy (RT) for lung cancer, however, the optimal practice for diagnosis, management, and follow-up for RP remains unclear. We thus sought to establish expert consensus recommendations through a Delphi Consensus study. Methods: In Round 1, open questions were distributed to 31 expert clinicians treating thoracic malignancies. In Round 2, participants rated agreement/disagreement with statements derived from Round 1 answers using a 5-point Likert scale. Consensus was defined as ≥ 75 % agreement. Statements that did not achieve consensus were modified and re-tested in Round 3. Results: Response rate was 74 % in Round 1 (n = 23/31; 17 oncologists, 6 pulmonologists); 82 % in Round 2 (n = 19/23; 15 oncologists, 4 pulmonologists); and 100 % in Round 3 (n = 19/19). Thirty-nine of 65 Round 2 statements achieved consensus; a further 10 of 26 statements achieved consensus in Round 3. In Round 2, there was agreement that risk stratification/mitigation includes patient factors; optimal treatment planning; the basis for diagnosis of RP; and that oncologists and pulmonologists should be involved in treatment. For uncomplicated radiation pneumonitis, an equivalent to 60 mg oral prednisone per day, with consideration of gastroprotection, is a typical initial regimen. However, in this study, no consensus was achieved for dosing recommendation. Initial steroid dose should be administered for a duration of 2 weeks, followed by a gradual, weekly taper (equivalent to 10 mg prednisone decrease per week). For severe pneumonitis, IV methylprednisolone is recommended for 3 days prior to initiating oral corticosteroids. Final consensus statements included that the treatment of RP should be multidisciplinary, the uncertainty of whether pneumonitis is drug versus radiation-induced, and the importance risk stratification, especially in the scenario of interstitial lung disease. Conclusions: This Delphi study achieved consensus recommendations and provides practical guidance on diagnosis and management of RP.